An adaptive phase I/II, dose-ranging study to evaluate the safety and feasibility of busulfan conditioning prior to transplant of CD4+ T lymphocytes and CD34+ haematopoietic stem/progenitor cells (HSPCs) transduced with LVSH5/C46 (CAL-1), in adults diagnosed at primary HIV-1 infection who are established on effective combination antiretroviral therapy (ART)

Trial Profile

An adaptive phase I/II, dose-ranging study to evaluate the safety and feasibility of busulfan conditioning prior to transplant of CD4+ T lymphocytes and CD34+ haematopoietic stem/progenitor cells (HSPCs) transduced with LVSH5/C46 (CAL-1), in adults diagnosed at primary HIV-1 infection who are established on effective combination antiretroviral therapy (ART)

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Cal-1-transduced haematopoietic stem progenitor cells (Primary) ; Busulfan
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Calimmune
  • Most Recent Events

    • 13 Sep 2017 Status changed from suspended to withdrawn prior to enrolment.
    • 06 Sep 2016 Status changed from recruiting to suspended.
    • 08 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top